Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Regulatory News

Date Source Headline
4th Mar 2020 7:00 am RNS Filing of Form 20-F with SEC
3rd Mar 2020 11:00 am RNS Annual Financial Report
2nd Mar 2020 3:00 pm RNS Total Voting Rights
2nd Mar 2020 7:00 am RNS Divestment of hypertension medicines completed
27th Feb 2020 7:00 am RNS Director/PDMR Shareholding
25th Feb 2020 7:00 am RNS AstraZeneca divests global rights to Movantik
19th Feb 2020 7:00 am RNS Director/PDMR Shareholding
14th Feb 2020 7:00 am RNS AZN: Full-year and Q4 2019 results
3rd Feb 2020 3:00 pm RNS Total Voting Rights
27th Jan 2020 7:00 am RNS Enhertu Phase II trial met primary endpoint
27th Jan 2020 7:00 am RNS Brilinta met primary endpoint in stroke trial
27th Jan 2020 7:00 am RNS AstraZeneca divests hypertension medicines
27th Jan 2020 7:00 am RNS AstraZeneca to recover brazikumab (MEDI2070)
20th Jan 2020 7:00 am RNS FDA grants Lynparza Priority Review for PROfound
20th Jan 2020 7:00 am RNS Imfinzi, tremelimumab granted ODD in liver cancer
13th Jan 2020 7:01 am RNS Lynparza granted FDA Priority Review for PAOLA-1
13th Jan 2020 7:00 am RNS Update on Epanova Phase III STRENGTH trial
6th Jan 2020 7:01 am RNS Farxiga granted FDA heart failure Priority Review
6th Jan 2020 7:00 am RNS Lokelma approved in China for hyperkalaemia
2nd Jan 2020 3:00 pm RNS Total Voting Rights
30th Dec 2019 7:00 am RNS US FDA approved Lynparza for pancreatic cancer
23rd Dec 2019 7:00 am RNS Triple-combination approved in China for COPD
23rd Dec 2019 7:00 am RNS Enhertu (trastuzumab deruxtecan) approved in US
20th Dec 2019 7:00 am RNS AstraZeneca divests rights to Arimidex and Casodex
17th Dec 2019 6:06 pm RNS FDA panel backs Lynparza use for pancreatic cancer
16th Dec 2019 7:00 am RNS Seroquel rights agreement complete: Europe, Russia
12th Dec 2019 7:00 am RNS Imfinzi approved in China for Stage III NSCLC
11th Dec 2019 1:00 pm RNS Trastuzumab deruxtecan achieves ORR of 60.9%
5th Dec 2019 7:00 am RNS Lynparza approved in China for 1L BRCAm ovarian
3rd Dec 2019 7:00 am RNS AstraZeneca divests Seroquel rights: US and Canada
2nd Dec 2019 3:00 pm RNS Block listing Interim Review
2nd Dec 2019 3:00 pm RNS Total Voting Rights
29th Nov 2019 7:00 am RNS Imfinzi granted FDA Priority Review for SCLC
21st Nov 2019 6:15 pm RNS Calquence approved in CLL in the US
15th Nov 2019 7:00 am RNS Qtrilmet approved in the EU for treatment of T2D
14th Nov 2019 7:00 am RNS FDA accepts regulatory submission for selumetinib
12th Nov 2019 7:00 am RNS Anifrolumab demonstrated superiority in TULIP 2
11th Nov 2019 7:00 am RNS Roxadustat pooled analyses: no increased CV risk
8th Nov 2019 7:00 am RNS Roxadustat significantly increased haemoglobin
6th Nov 2019 2:10 pm RNS Calquence data to show improved progression-free
FTSE 100 Latest
Value8,157.55
Change-317.19